Holen Sie sich die Stockscreener-App
40.00
2.08%
-0.85
Vorhandelsmarkt:
41.09
1.09
+2.73%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$40.85
Offen:
$41.22
24-Stunden-Volumen:
783.76K
Relative Volume:
0.95
Marktkapitalisierung:
$3.69B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-6.1824
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-4.92%
1M Leistung:
-11.01%
6M Leistung:
-8.86%
1J Leistung:
-7.92%
1-Tages-Spanne:
$39.99
$41.50
1-Wochen-Bereich:
$39.79
$44.52
52-Wochen-Spanne:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
40.00 | 3.69B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Awards 7,750 Restricted Stock Units to New Non-Executive Officers in Retention Plan - StockTitan
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat
Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World
Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth - Investing.com India
JPMorgan Chase & Co. Has $11.84 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for 2024 -January 12, 2025 at 11:00 am EST - Marketscreener.com
Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Consensus Target Price from Brokerages - Defense World
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder - MSN
Hypophosphatasia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma, Alexion - Barchart
Hypophosphatasia Market Predicted to See Upsurge Through 2032, - openPR
Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth - Investing.com Australia
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com South Africa
Ultragenyx Pharmaceutical’s SWOT analysis: rare disease stock poised for growth - Investing.com Nigeria
RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug - Investing.com Nigeria
RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug By Investing.com - Investing.com South Africa
Top 10 startups in Rare Diseases in Bay Area, United States in Jan, 2025 - Tracxn
Political petulance, complacency halt pediatric priority review program - BioCentury
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 7.2% HigherTime to Buy? - MarketBeat
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
European Commission (EC) Extends the Approval of Evkeeza® - GlobeNewswire
Ultragenyx's Evkeeza Makes Breakthrough: First EU Treatment for Infant HoFH Patients - StockTitan
Principal Financial Group Inc. Has $4.80 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx asks FDA to review gene therapy for Sanfilippo A - Sanfilippo News
Ultragenyx CEO Emil Kakkis sells $495,231 in company stock By Investing.com - Investing.com Canada
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):